M·CAM | Catalyst Pharmaceutical’s Firdapse price hike – Patently Obvious®
24712
post-template-default,single,single-post,postid-24712,single-format-standard,ajax_fade,page_not_loaded,,select-theme-ver-4.1,wpb-js-composer js-comp-ver-6.1,vc_responsive
February 14, 2019 In Business Events, News Archive, Patently Obvious®

Catalyst Pharmaceutical’s Firdapse price hike – Patently Obvious®

3,4-DAP

Image courtesy: Edgar181 [Public domain], from Wikimedia Commons

 

 

Senator Bernie Sanders wrote an open letter to Catalyst Pharmaceuticals on the 4th of February regarding their newly FDA approved drug to treat Lambert-Eaton Myasthenic Syndrome, saying “Catalyst’s decision to set the annual list price at $375,000 is not only a blatant fleecing of American taxpayers, but is also an immoral exploitation of patients who need this medication.”

Seeing this, M·CAM decided to investigate. What follows is a report on a company that has leveraged the patent system and orphan drug act against their intended use to profit on the suffering of vulnerable patients.

Download the Patently Obvious® report here

 

No Comments

Sorry, the comment form is closed at this time.